Skip to content
Clinical Trial Events
19th Clinical Trials on Alzheimer's Disease (CTAD) 2026

Talk

Oral Communications

Mon, Nov 16, 2026 · 3:50–4:50 PM EST Ballroom - 4th floor, Boston Marriott Copley Place

About this session

Oral communications: OC1 Top-Line Results of SINGER: A Two-Year Randomized Controlled Trial of Multidomain Lifestyle Intervention to Prevent Cognitive Decline; OC2 POLARIS-AD: A Global Phase 3 Trial of AR1001 in Early Alzheimer's Disease: Efficacy Outcomes at 52 Weeks and Safety Through the Extension Phase; OC3 Ultrasensitive Immunoassay for Plasma eMTBR-243 Quantification; OC4 Plasma p-tau217 outperforms neuroimaging biomarkers in predicting the risk of cognitive impairment in a multi-cohort study.

Speakers